



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
September 2025



FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

TABLE OF CONTENTS (continued)

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

NORTHERN HEALTH


- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers

INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
September 2025
N = 7737




Health Authority	Male	Female	All
FRASER	1654	498	2152
VANCOUVER ISLAND	887	178	1065
VANCOUVER COASTAL	3200	450	3650
INTERIOR	481	125	606
NORTHERN	170	84	254
	6392	1335	7727
Unknown/not stated			10
Total			7737

On antiretroviral treatment is defined as being on treatment in the current month
Unknown/not stated is defined as being on treatment in the current month, and city of residence is unknown
Male & Female refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
September 2020 - September 2025



1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
OCT-2023	7610	4808	63.2	615	8.1	611	8.0	897	11.8	618	8.1	61	0.8
NOV-2023	7612	4799	63.0	611	8.0	599	7.9	918	12.1	624	8.2	61	0.8
DEC-2023	7603	4808	63.2	593	7.8	596	7.8	936	12.3	614	8.1	56	0.7
JAN-2024	7642	4856	63.5	583	7.6	585	7.7	952	12.5	609	8.0	57	0.7
FEB-2024	7647	4861	63.6	564	7.4	586	7.7	971	12.7	609	8.0	56	0.7
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	618	8.1	58	0.8
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1000	13.0	621	8.1	57	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1023	13.3	607	7.9	53	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1033	13.4	606	7.9	56	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1060	13.7	605	7.8	54	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1081	14.0	602	7.8	51	0.7
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1124	14.6	595	7.7	53	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1167	15.1	593	7.7	48	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1176	15.3	581	7.5	46	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1199	15.5	588	7.6	49	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1234	15.9	586	7.6	45	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1264	16.4	577	7.5	47	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1291	16.8	572	7.4	44	0.6
APR-2025	7719	4947	64.1	394	5.1	432	5.6	1320	17.1	584	7.6	42	0.5
MAY-2025	7705	4911	63.7	386	5.0	423	5.5	1369	17.8	573	7.4	43	0.6
JUN-2025	7713	4893	63.4	371	4.8	417	5.4	1427	18.5	565	7.3	40	0.5
JUL-2025	7772	4940	63.6	359	4.6	411	5.3	1457	18.7	564	7.3	41	0.5
AUG-2025	7762	4921	63.4	346	4.5	407	5.2	1478	19.0	565	7.3	45	0.6
SEP-2025	7737	4897	63.3	334	4.3	392	5.1	1502	19.4	567	7.3	45	0.6

n is number of participants on the specified regimen class in the specified month


% is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
September 2020 - September 2025




1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
OCT-2023	7474	1895	25.4	4573	61.2	2904	38.9	3766	50.4	935	12.5	14	0.2
NOV-2023	7474	1866	25.0	4585	61.4	2891	38.7	3783	50.6	918	12.3	15	0.2
DEC-2023	7464	1831	24.5	4595	61.6	2874	38.5	3820	51.2	895	12.0	13	0.2
JAN-2024	7502	1831	24.4	4633	61.8	2881	38.4	3866	51.5	890	11.9	13	0.2
FEB-2024	7504	1795	23.9	4641	61.9	2868	38.2	3896	51.9	864	11.5	13	0.2
MAR-2024	7493	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	7525	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	7544	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	7544	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	7570	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	7563	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	7551	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	7577	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	7555	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	7572	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	7591	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	7547	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	7537	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1
APR-2025	7557	1304	17.3	4909	65.0	2664	35.3	4374	57.9	655	8.7	6	0.1
MAY-2025	7537	1242	16.5	4894	64.9	2654	35.2	4373	58.0	630	8.4	7	0.1
JUN-2025	7540	1196	15.9	4910	65.1	2647	35.1	4406	58.4	620	8.2	7	0.1
JUL-2025	7593	1137	15.0	4981	65.6	2629	34.6	4482	59.0	615	8.1	7	0.1
AUG-2025	7579	1076	14.2	4993	65.9	2596	34.3	4512	59.5	594	7.8	7	0.1
SEP-2025	7556	1043	13.8	4990	66.0	2576	34.1	4528	59.9	571	7.6	7	0.1

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
September 2020 - September 2025




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

MON-YYYY	Total Participants	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
		n	%	n	%	n	%	n	%	n	%
OCT-2023	1198	273	22.8	893	74.5	35	2.9	0	0.0	0	0.00
NOV-2023	1184	260	22.0	890	75.2	35	3.0	0	0.0	0	0.00
DEC-2023	1156	248	21.5	876	75.8	33	2.9	0	0.0	0	0.00
JAN-2024	1138	241	21.2	866	76.1	33	2.9	0	0.0	0	0.00
FEB-2024	1111	229	20.6	852	76.7	31	2.8	0	0.0	0	0.00
MAR-2024	1094	225	20.6	840	76.8	30	2.7	0	0.0	0	0.00
APR-2024	1088	224	20.6	835	76.8	31	2.9	0	0.0	0	0.00
MAY-2024	1081	221	20.4	828	76.6	33	3.1	0	0.0	0	0.00
JUN-2024	1059	214	20.2	813	76.8	33	3.1	0	0.0	0	0.00
JUL-2024	1052	216	20.5	805	76.5	33	3.1	0	0.0	0	0.00
AUG-2024	1021	208	20.4	784	76.8	31	3.0	0	0.0	0	0.00
SEP-2024	1001	203	20.3	772	77.1	27	2.7	0	0.0	0	0.00
OCT-2024	977	197	20.2	754	77.2	27	2.8	0	0.0	0	0.00
NOV-2024	957	190	19.9	742	77.5	28	2.9	0	0.0	0	0.00
DEC-2024	947	184	19.4	738	77.9	26	2.8	0	0.0	0	0.00
JAN-2025	922	177	19.2	726	78.7	23	2.5	0	0.0	0	0.00
FEB-2025	891	168	18.9	700	78.6	24	2.7	0	0.0	0	0.00
MAR-2025	875	167	19.1	686	78.4	24	2.7	0	0.0	0	0.00
APR-2025	860	153	17.8	684	79.5	24	2.8	0	0.0	0	0.00
MAY-2025	840	151	18.0	666	79.3	24	2.9	0	0.0	0	0.00
JUN-2025	823	150	18.2	652	79.2	23	2.8	0	0.0	0	0.00
JUL-2025	806	146	18.1	639	79.3	23	2.9	0	0.0	0	0.00
AUG-2025	788	142	18.0	624	79.2	23	2.9	0	0.0	0	0.00
SEP-2025	768	140	18.2	607	79.0	22	2.9	0	0.0	0	0.00

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Ritonavir - greater than 400 mg total daily dose

1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
September 2020 - September 2025




1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
OCT-2023	932	238 25.5	216 23.2	89 9.6	220 23.6	173 18.6
NOV-2023	928	242 26.1	209 22.5	88 9.5	219 23.6	173 18.6
DEC-2023	929	250 26.9	205 22.1	87 9.4	213 22.9	176 19.0
JAN-2024	921	250 27.1	200 21.7	83 9.0	208 22.6	181 19.7
FEB-2024	919	257 28.0	192 20.9	82 8.9	207 22.5	182 19.8
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0
APR-2025	818	317 38.8	137 16.8	61 7.5	128 15.7	177 21.6
MAY-2025	809	313 38.7	129 16.0	60 7.4	126 15.6	181 22.4
JUN-2025	812	315 38.8	127 15.6	60 7.4	122 15.0	190 23.4
JUL-2025	809	322 39.8	124 15.3	56 6.9	113 14.0	194 24.0
AUG-2025	805	329 40.9	117 14.5	57 7.1	109 13.5	198 24.6
SEP-2025	806	335 41.6	116 14.4	52 6.5	107 13.3	199 24.7

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class

1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
September 2020 - September 2025






1.11 Number of Participants on Integrase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
OCT-2023	6294	3298 52.4	7 0.1	2523 40.1	241 3.8	248 3.9
NOV-2023	6311	3327 52.7	9 0.1	2518 39.9	233 3.7	244 3.9
DEC-2023	6330	3365 53.2	13 0.2	2506 39.6	226 3.6	237 3.7
JAN-2024	6389	3418 53.5	16 0.3	2520 39.4	224 3.5	234 3.7
FEB-2024	6417	3453 53.8	15 0.2	2516 39.2	219 3.4	231 3.6
MAR-2024	6435	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	6483	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	6511	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	6528	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	6584	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	6593	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	6610	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	6680	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	6681	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	6720	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	6762	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	6754	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	6767	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6
APR-2025	6834	3985 58.3	49 0.7	2488 36.4	176 2.6	167 2.4
MAY-2025	6840	3987 58.3	57 0.8	2478 36.2	174 2.5	165 2.4
JUN-2025	6868	4021 58.6	67 1.0	2483 36.2	170 2.5	162 2.4
JUL-2025	6952	4102 59.0	75 1.1	2478 35.6	168 2.4	159 2.3
AUG-2025	6955	4133 59.4	81 1.2	2453 35.3	162 2.3	159 2.3
SEP-2025	6957	4151 59.7	92 1.3	2435 35.0	157 2.3	152 2.2

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
September 2020 - September 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total Participants	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
OCT-2023	20	2	10.0	18	90.0	1	5.0
NOV-2023	19	1	5.3	17	89.5	1	5.3
DEC-2023	19	2	10.5	16	84.2	1	5.3
JAN-2024	21	2	9.5	18	85.7	1	4.8
FEB-2024	21	2	9.5	18	85.7	1	4.8
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5
APR-2025	19	2	10.5	15	79.0	2	10.5
MAY-2025	17	2	11.8	14	82.4	1	5.9
JUN-2025	19	2	10.5	15	79.0	2	10.5
JUL-2025	22	2	9.1	16	72.7	4	18.2
AUG-2025	24	2	8.3	16	66.7	6	25.0
SEP-2025	25	2	8.0	15	60.0	8	32.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
September 2020 - September 2025




1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

MON-YYYY	Total Participants	1 drug		2 drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%	n	%
OCT-2023	7610	2	0.0	897	11.8	6237	82.0	433	5.7	41	0.5
NOV-2023	7612	2	0.0	918	12.1	6210	81.6	441	5.8	41	0.5
DEC-2023	7603	2	0.0	936	12.3	6191	81.4	434	5.7	40	0.5
JAN-2024	7642	2	0.0	952	12.5	6214	81.3	432	5.7	42	0.6
FEB-2024	7647	3	0.0	971	12.7	6198	81.1	436	5.7	39	0.5
MAR-2024	7636	2	0.0	991	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	7670	2	0.0	1001	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	7687	2	0.0	1024	13.3	6188	80.5	434	5.7	39	0.5
JUN-2024	7687	1	0.0	1034	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	7718	2	0.0	1061	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	7709	2	0.0	1082	14.0	6155	79.8	431	5.6	39	0.5
SEP-2024	7697	2	0.0	1125	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	7725	1	0.0	1169	15.1	6087	78.8	427	5.5	41	0.5
NOV-2024	7703	1	0.0	1177	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	7720	2	0.0	1200	15.5	6054	78.4	424	5.5	40	0.5
JAN-2025	7739	2	0.0	1235	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	7696	2	0.0	1265	16.4	5977	77.7	414	5.4	38	0.5
MAR-2025	7689	4	0.1	1292	16.8	5942	77.3	414	5.4	37	0.5
APR-2025	7719	3	0.0	1321	17.1	5939	76.9	419	5.4	37	0.5
MAY-2025	7705	4	0.1	1370	17.8	5882	76.3	410	5.3	39	0.5
JUN-2025	7713	4	0.1	1428	18.5	5845	75.8	396	5.1	40	0.5
JUL-2025	7772	2	0.0	1460	18.8	5874	75.6	399	5.1	37	0.5
AUG-2025	7762	5	0.1	1482	19.1	5839	75.2	396	5.1	40	0.5
SEP-2025	7737	3	0.0	1508	19.5	5790	74.8	398	5.1	38	0.5

n is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count
September 2020 - September 2025





1.17 Distribution of Active Participants by CD4 Count

Month	# of Pts with CD4: Unreported	# of Pts with CD4: < 200	# of Pts with CD4: 200 - 349	# of Pts with CD4: 350 - 500	# of Pts with CD4: > 500
OCT-2023	1334	242	543	943	3727
NOV-2023	1370	237	542	937	3689
DEC-2023	1411	237	530	917	3703
JAN-2024	1447	238	529	916	3679
FEB-2024	1486	242	503	911	3673
MAR-2024	1512	255	498	924	3649
APR-2024	1554	253	486	944	3627
MAY-2024	1588	248	486	923	3661
JUN-2024	1623	247	493	886	3680
JUL-2024	1685	248	493	912	3682
AUG-2024	1726	251	491	910	3660
SEP-2024	1744	241	489	935	3639
OCT-2024	1780	243	499	948	3624
NOV-2024	1813	234	505	917	3652
DEC-2024	1840	232	508	928	3658
JAN-2025	1862	233	509	939	3650
FEB-2025	1880	223	511	930	3640
MAR-2025	1903	225	508	934	3620
APR-2025	1938	230	500	902	3667
MAY-2025	1960	229	493	875	3654
JUN-2025	1997	223	477	899	3655
JUL-2025	2023	215	510	883	3696
AUG-2025	2068	217	503	877	3714
SEP-2025	2116	220	492	869	3718


CD4 value (cells/ μ L) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record



1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment
September 2020 - September 2025




1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

MON-YYYY	Total	INSTI 2 N(t)RTIs		Boosted PI 2 N(t)RTIs		NNRTI 2 N(t)RTIs		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
OCT-2023	10	9	90.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0
NOV-2023	9	7	77.8	0	0.0	0	0.0	1	11.1	1	11.1	0	0.0
DEC-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
JAN-2024	11	9	81.8	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
FEB-2024	11	11	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
APR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAY-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUL-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2025	13	12	92.3	0	0.0	0	0.0	1	7.7	0	0.0	0	0.0

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
n is number of participants on the specified regimen category in the specified month
% is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
September 2020 - September 2025




1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program

MON-YYYY	# of First Starts	# of Pts with CD4: Unreported		# of Pts with CD4: < 200		# of Pts with CD4: 200 - 349		# of Pts with CD4: 350 - 500		# of Pts with CD4: > 500	
		n	%	n	%	n	%	n	%	n	%
OCT-2023	10	1	10.0	1	10.0	3	30.0	2	20.0	3	30.0
NOV-2023	9	1	11.1	2	22.2	0	0.0	2	22.2	4	44.4
DEC-2023	13	1	7.7	1	7.7	3	23.1	0	0.0	8	61.5
JAN-2024	11	1	9.1	4	36.4	2	18.2	1	9.1	3	27.3
FEB-2024	11	1	9.1	3	27.3	4	36.4	2	18.2	1	9.1
MAR-2024	13	2	15.4	5	38.5	1	7.7	1	7.7	4	30.8
APR-2024	20	0	0.0	4	20.0	6	30.0	1	5.0	9	45.0
MAY-2024	16	1	6.3	5	31.3	3	18.8	1	6.3	6	37.5
JUN-2024	23	0	0.0	2	8.7	10	43.5	4	17.4	7	30.4
JUL-2024	10	1	10.0	1	10.0	3	30.0	3	30.0	2	20.0
AUG-2024	15	0	0.0	5	33.3	4	26.7	3	20.0	3	20.0
SEP-2024	7	0	0.0	1	14.3	4	57.1	1	14.3	1	14.3
OCT-2024	15	0	0.0	6	40.0	3	20.0	3	20.0	3	20.0
NOV-2024	9	0	0.0	3	33.3	3	33.3	2	22.2	1	11.1
DEC-2024	10	0	0.0	4	40.0	2	20.0	2	20.0	2	20.0
JAN-2025	14	0	0.0	6	42.9	2	14.3	5	35.7	1	7.1
FEB-2025	9	0	0.0	2	22.2	1	11.1	3	33.3	3	33.3
MAR-2025	12	1	8.3	5	41.7	2	16.7	2	16.7	2	16.7
APR-2025	12	1	8.3	3	25.0	2	16.7	2	16.7	4	33.3
MAY-2025	17	1	5.9	6	35.3	3	17.7	5	29.4	2	11.8
JUN-2025	8	0	0.0	2	25.0	3	37.5	2	25.0	1	12.5
JUL-2025	8	2	25.0	0	0.0	2	25.0	2	25.0	2	25.0
AUG-2025	17	2	11.8	3	17.7	1	5.9	6	35.3	5	29.4
SEP-2025	13	1	7.7	5	38.5	0	0.0	4	30.8	3	23.1

First Starts defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)
Pre-entry CD4 (cells/ μ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
September 2020 - September 2025



1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

MON-YYYY	On Antiretroviral (ARV) Treatment	Ever Tested	NNRTI		N(t)RTI		PI		INSTI	
			n	%	n	%	n	%	n	%
OCT-2023	7579	6394	1307	20.4	1648	25.8	552	8.6	100	1.6
NOV-2023	7578	6388	1307	20.5	1644	25.7	558	8.7	102	1.6
DEC-2023	7574	6374	1306	20.5	1634	25.6	553	8.7	101	1.6
JAN-2024	7613	6399	1306	20.4	1645	25.7	549	8.6	103	1.6
FEB-2024	7620	6409	1301	20.3	1647	25.7	562	8.8	103	1.6
MAR-2024	7616	6393	1294	20.2	1638	25.6	555	8.7	106	1.7
APR-2024	7647	6411	1299	20.3	1637	25.5	563	8.8	103	1.6
MAY-2024	7666	6419	1301	20.3	1637	25.5	566	8.8	104	1.6
JUN-2024	7678	6419	1306	20.4	1626	25.3	560	8.7	102	1.6
JUL-2024	7697	6425	1315	20.5	1636	25.5	557	8.7	108	1.7
AUG-2024	7686	6410	1304	20.3	1620	25.3	547	8.5	106	1.7
SEP-2024	7674	6391	1299	20.3	1622	25.4	553	8.7	103	1.6
OCT-2024	7702	6408	1285	20.1	1618	25.3	555	8.7	100	1.6
NOV-2024	7674	6374	1279	20.1	1614	25.3	544	8.5	98	1.5
DEC-2024	7693	6373	1279	20.1	1601	25.1	541	8.5	102	1.6
JAN-2025	7712	6374	1272	20.0	1588	24.9	529	8.3	106	1.7
FEB-2025	7673	6328	1268	20.0	1575	24.9	530	8.4	107	1.7
MAR-2025	7668	6327	1259	19.9	1561	24.7	531	8.4	109	1.7
APR-2025	7701	6344	1263	19.9	1568	24.7	524	8.3	105	1.7
MAY-2025	7676	6322	1265	20.0	1561	24.7	529	8.4	105	1.7
JUN-2025	7692	6321	1262	20.0	1554	24.6	521	8.2	105	1.7
JUL-2025	7749	6359	1265	19.9	1559	24.5	520	8.2	106	1.7
AUG-2025	7739	6343	1264	19.9	1563	24.6	522	8.2	108	1.7
SEP-2025	7718	6307	1254	19.9	1556	24.7	515	8.2	107	1.7

On Antiretroviral (ARV) Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever Tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

n: number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

% is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug the corresponding drug class in BC.


Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8. HIVdb scores ≥ 15 are classified as "resistant".

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance
September 2020 - September 2025



1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance

MON-YYYY	On Antiretroviral Treatment	Ever Tested	0-Class (Wild Type)		1-Class		2-Class		3 or more Class	
			n	%	n	%	n	%	n	%
OCT-2023	7579	6394	4086	63.9	1282	20.1	758	11.9	268	4.2
NOV-2023	7578	6388	4076	63.8	1288	20.2	754	11.8	270	4.2
DEC-2023	7574	6374	4070	63.9	1287	20.2	749	11.8	268	4.2
JAN-2024	7613	6399	4087	63.9	1293	20.2	751	11.7	268	4.2
FEB-2024	7620	6409	4098	63.9	1285	20.1	755	11.8	271	4.2
MAR-2024	7616	6393	4096	64.1	1277	20.0	749	11.7	271	4.2
APR-2024	7647	6411	4103	64.0	1292	20.2	743	11.6	273	4.3
MAY-2024	7666	6419	4107	64.0	1292	20.1	749	11.7	271	4.2
JUN-2024	7678	6419	4117	64.1	1286	20.0	743	11.6	273	4.3
JUL-2024	7697	6425	4110	64.0	1294	20.1	746	11.6	275	4.3
AUG-2024	7686	6410	4115	64.2	1288	20.1	737	11.5	270	4.2
SEP-2024	7674	6391	4098	64.1	1286	20.1	735	11.5	272	4.3
OCT-2024	7702	6408	4120	64.3	1288	20.1	734	11.5	266	4.2
NOV-2024	7674	6374	4098	64.3	1282	20.1	732	11.5	262	4.1
DEC-2024	7693	6373	4104	64.4	1277	20.0	733	11.5	259	4.1
JAN-2025	7712	6374	4115	64.6	1277	20.0	731	11.5	251	3.9
FEB-2025	7673	6328	4078	64.4	1274	20.1	724	11.4	252	4.0
MAR-2025	7668	6327	4086	64.6	1276	20.2	715	11.3	250	4.0
APR-2025	7701	6344	4104	64.7	1273	20.1	718	11.3	249	3.9
MAY-2025	7676	6322	4082	64.6	1273	20.1	718	11.4	249	3.9
JUN-2025	7692	6321	4091	64.7	1268	20.1	716	11.3	246	3.9
JUL-2025	7749	6359	4121	64.8	1276	20.1	716	11.3	246	3.9
AUG-2025	7739	6343	4103	64.7	1274	20.1	719	11.3	247	3.9
SEP-2025	7718	6307	4082	64.7	1267	20.1	711	11.3	247	3.9

Number of Antiretroviral (ARV) Drug Classes with Resistance considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores ≥ 15 are classified as "resistant".

On Antiretroviral Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of September 2025

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
Pre-1993	31	48	184	175	9	34	(30, 39)	93	540	(360, 710)	168	<40	(<40, <40)
1993	30	120	121	107	14	34	(29, 39)	72	610	(425, 798)	113	<40	(<40, <40)
1994	28	71	71	59	12	34	(30, 37)	48	625	(433, 935)	64	<40	(<40, <40)
1995	28	123	124	105	19	34	(29, 39)	72	620	(478, 778)	114	<40	(<40, <40)
1996	27	311	313	272	41	35	(30, 39)	179	620	(440, 840)	279	<40	(<40, <40)
1997	24	262	268	243	25	34	(30, 38)	159	630	(420, 860)	241	<40	(<40, <40)
1998	24	185	194	158	36	34	(30, 40)	130	575	(423, 760)	172	<40	(<40, <40)
1999	24	160	161	124	37	36	(31, 41)	107	600	(395, 795)	145	<40	(<40, <40)
2000	24	120	123	100	23	38	(34, 44)	78	660	(473, 795)	109	<40	(<40, <40)
2001	23	118	120	97	23	37	(32, 44)	74	620	(418, 820)	108	<40	(<40, <40)
2002	23	111	121	104	17	40	(31, 46)	76	565	(438, 710)	108	<40	(<40, <40)
2003	22	140	150	129	21	39	(34, 45)	97	610	(430, 820)	126	<40	(<40, <40)
2004	21	142	164	128	36	40	(34, 44)	108	635	(415, 833)	154	<40	(<40, <40)
2005	20	178	194	154	40	40	(34, 47)	139	640	(460, 865)	176	<40	(<40, <40)
2006	19	173	192	155	37	41	(33, 47)	136	625	(440, 843)	175	<40	(<40, <40)
2007	18	228	247	214	33	41	(35, 46)	165	660	(450, 860)	219	<40	(<40, <40)
2008	17	267	301	246	55	42	(34, 48)	218	680	(500, 860)	271	<40	(<40, <40)
2009	16	296	326	268	58	41	(34, 47)	215	650	(475, 885)	291	<40	(<40, <40)
2010	15	257	296	235	61	40	(32, 45)	204	660	(500, 860)	269	<40	(<40, <40)
2011	14	304	349	285	64	41	(33, 48)	224	710	(490, 920)	312	<40	(<40, <40)
2012	13	273	313	252	61	41	(32, 49)	201	720	(540, 950)	285	<40	(<40, <40)
2013	12	246	294	235	59	41	(32, 49)	191	670	(494, 875)	264	<40	(<40, <40)
2014	11	224	287	244	43	40	(31, 50)	186	760	(560, 990)	247	<40	(<40, <40)
2015	10	195	278	237	41	41	(31, 51)	182	715	(510, 917)	248	<40	(<40, <40)
2016	9	177	250	205	45	38	(32, 49)	175	670	(480, 910)	218	<40	(<40, <40)
2017	8	156	221	192	29	36	(28, 45)	150	675	(540, 930)	199	<40	(<40, <40)
2018	7	132	202	162	40	40	(31, 48)	133	800	(560, 1008)	175	<40	(<40, <40)
2019	6	131	247	205	42	38	(29, 48)	185	740	(530, 900)	212	<40	(<40, <40)
2020	5	102	200	151	49	37	(30, 49)	152	740	(538, 963)	175	<40	(<40, <40)

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of September 2025 (cont.)

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
2021	4	110	201	170	31	38	(30, 47)	168	660	(453, 860)	138	<40	(<40, <40)
2022	3	105	270	223	47	38	(31, 47)	247	705	(518, 913)	208	<40	(<40, <40)
2023	2	111	312	255	57	35	(30, 45)	285	640	(480, 840)	238	<40	(<40, <40)
2024	1	136	341	276	65	36	(29, 45)	320	610	(445, 810)	292	<40	(<40, <40)
2025	0	105	283	219	64	36	(30, 46)	268	572	(355, 740)	267	<40	(<40, 42)
Total:		5817	7718	6384	1334								

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment

MON-YYYY	Total Participants	Median # of Treatment days	(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
				Median	(Q1, Q3)		Median	(Q1, Q3)
OCT-2023	7610	803	5455	640	(450, 860)	6812	<40	(<40, <40)
NOV-2023	7612	795	5405	640	(450, 860)	6841	<40	(<40, <40)
DEC-2023	7603	798	5387	650	(460, 860)	6829	<40	(<40, <40)
JAN-2024	7642	792	5362	640	(460, 860)	6815	<40	(<40, <40)
FEB-2024	7647	781	5329	650	(460, 870)	6865	<40	(<40, <40)
MAR-2024	7636	790	5326	640	(450, 870)	6872	<40	(<40, <40)
APR-2024	7670	786	5310	640	(450, 870)	6843	<40	(<40, <40)
MAY-2024	7687	787	5318	650	(460, 880)	6897	<40	(<40, <40)
JUN-2024	7687	784	5306	650	(460, 870)	6922	<40	(<40, <40)
JUL-2024	7718	786	5335	650	(460, 870)	7010	<40	(<40, <40)
AUG-2024	7709	782	5312	650	(460, 873)	6938	<40	(<40, <40)
SEP-2024	7697	791	5304	650	(460, 870)	6905	<40	(<40, <40)
OCT-2024	7725	787	5314	650	(460, 870)	6899	<40	(<40, <40)
NOV-2024	7703	793	5308	650	(460, 880)	6876	<40	(<40, <40)
DEC-2024	7720	796	5326	650	(460, 880)	6914	<40	(<40, <40)
JAN-2025	7739	792	5331	650	(450, 880)	6883	<40	(<40, <40)
FEB-2025	7696	800	5304	650	(460, 880)	6871	<40	(<40, <40)
MAR-2025	7689	792	5287	650	(450, 875)	6813	<40	(<40, <40)
APR-2025	7719	779	5299	660	(460, 880)	6891	<40	(<40, <40)
MAY-2025	7705	787	5251	660	(460, 880)	6861	<40	(<40, <40)
JUN-2025	7713	785	5254	660	(460, 880)	6835	<40	(<40, <40)
JUL-2025	7772	773	5304	652	(460, 870)	6914	<40	(<40, <40)
AUG-2025	7762	780	5311	660	(460, 861)	6943	<40	(<40, <40)
SEP-2025	7737	792	5299	660	(460, 860)	6935	<40	(<40, <40)

Active participant defined as being on antiretroviral treatment in the specified month

Treatment days defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

CD4 and pVL tests defined as tests done in the specified month





2.3 BC-CfE HIV Treatment Program Enrolment

MON-YYYY	On ARV Treatment	Off ARV Treatment	Deceased	ARV Treatment naïve starts	ARV Treatment experienced starts	Newly interrupted ARV Treatment	Net Change
OCT-2023	7579	725	18	10	170	160	0
NOV-2023	7578	732	18	9	182	171	-1
DEC-2023	7574	741	14	13	169	169	-4
JAN-2024	7613	699	16	11	204	159	39
FEB-2024	7620	696	17	11	184	165	7
MAR-2024	7616	710	12	13	183	185	-4
APR-2024	7647	693	17	20	197	168	31
MAY-2024	7666	692	12	16	191	173	19
JUN-2024	7678	707	5	23	173	177	12
JUL-2024	7697	696	15	10	185	159	19
AUG-2024	7686	711	13	15	164	168	-11
SEP-2024	7674	717	9	7	182	186	-12
OCT-2024	7702	710	8	15	200	172	28
NOV-2024	7674	747	14	9	181	199	-28
DEC-2024	7693	744	15	10	194	170	19
JAN-2025	7712	717	14	14	196	170	19
FEB-2025	7673	760	10	9	166	201	-39
MAR-2025	7668	760	12	12	175	177	-5
APR-2025	7701	737	9	12	192	157	33
MAY-2025	7676	758	18	17	167	188	-25
JUN-2025	7692	737	12	8	175	150	16
JUL-2025	7749	697	8	8	203	141	57
AUG-2025	7739	716	11	17	148	163	-10
SEP-2025	7718	768	6	13	189	213	-21

ARV: antiretroviral

On ARV Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

Off ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

Deceased: in the specified month, and on ARV treatment in the previous month

ARV Treatment naïve starts: participants starting ARV treatment in the specified month for the first time

ARV Treatment experienced starts: participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month

Newly Interrupted ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.


Net Change: the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)






3.1 Distribution of HIV Treatment Program Active Participants September 2025

BY HEALTH SERVICE DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV Treatment Program Active Participants September 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants September 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants
September 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE



*** Please refer to VIHA (432 and 434) on the next page







3.5 Distribution of HIV Treatment Program Active Participants September 2025



VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA

N = 1065



VICTORIA BY POSTAL CODE


N = 524






3.6 Distribution of HIV Treatment Program Active Participants September 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	0 - 29	0	0	0	0	N/A	*	*
	30 - 49	16	12	0	15	740	*	*
	50 - 64	12	11	0	13	750	*	*
	65+	7	7	0	6	570	*	*
	Total HSDA:	35	30	0	34	740	30	<40
KOOTENAY BOUNDARY	0 - 29	*	5	0	5	880	*	*
	30 - 49	*	11	0	12	735	*	*
	50 - 64	*	17	0	17	590	*	*
	65+	*	18	0	12	860	*	*
	Total HSDA:	57	51	0	46	750	41	<40
OKANAGAN	0 - 29	14	13	0	14	640	10	<40
	30 - 49	130	116	0	119	720	106	<40
	50 - 64	156	138	0	136	670	122	<40
	65+	89	81	0	82	565	75	<40
	Total HSDA:	389	348	0	351	660	313	<40
THOMPSON/CARIBOO/SHUSWAP	0 - 29	14	11	*	11	680	11	<40
	30 - 49	58	51	*	47	740	41	<40
	50 - 64	87	80	*	68	670	63	<40
	65+	37	35	*	31	630	33	<40
	Total HSDA:	196	177	<5	157	680	148	<40
Total HA:		677	606	<5	588	680	532	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	32	29	*	30	780	24	<40
	30 - 49	218	190	*	193	740	172	<40
	50 - 64	276	246	*	234	670	209	<40
	65+	151	141	*	131	590	127	<40
Total HA:		677	606	<5	588	680	532	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	540	481	*	465	670	427	<40
Female	137	125	*	123	700	105	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	606	56	680	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.2 Distribution of Participants by Program Duration INTERIOR Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	10 years or more	17	14	0	*	*	*	*
	5 years or more	11	11	0	*	*	*	*
	<5 years	7	5	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	35	30	0	34	740	30	<40
KOOTENAY BOUNDARY	10 years or more	43	38	0	*	*	*	*
	5 years or more	7	6	0	*	*	*	*
	<5 years	7	7	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	57	51	0	46	750	41	<40
OKANAGAN	10 years or more	252	226	0	225	670	200	<40
	5 years or more	56	48	0	50	680	45	<40
	<5 years	81	74	0	76	610	68	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	389	348	0	351	660	313	<40
THOMPSON/CARIBOO/SHUSWAP	10 years or more	121	110	*	98	680	90	<40
	5 years or more	26	22	*	18	760	21	<40
	<5 years	49	45	*	41	650	37	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	196	177	<5	157	680	148	<40
Total HA:		677	606	<5	588	680	532	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	433	388	*	*	*	*	*
	5 years or more	100	87	*	*	*	*	*
	<5 years	144	131	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		677	606	<5	588	680	532	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
EAST KOOTENAY	13	30	53	103
KOOTENAY BOUNDARY	15	37	77	141
OKANAGAN	51	332	245	1118
THOMPSON/CARIBOO/SHUSWAP	29	145	153	599
Total:	108	544	528	1961

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	133

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	0 - 29	29	27	*	29	784	25	<40
	30 - 49	115	96	*	83	740	90	<40
	50 - 64	155	143	*	101	650	122	<40
	65+	72	71	*	49	630	67	<40
	Total HSDA:	371	337	<5	262	680	304	<40
FRASER NORTH	0 - 29	49	45	*	44	660	45	<40
	30 - 49	380	346	*	303	720	326	<40
	50 - 64	361	337	*	240	680	322	<40
	65+	177	169	*	110	600	160	<40
	Total HSDA:	967	897	<5	697	680	853	<40
FRASER SOUTH	0 - 29	74	69	*	61	600	66	<40
	30 - 49	360	329	*	250	680	320	<40
	50 - 64	395	358	*	259	650	339	<40
	65+	169	162	*	119	550	156	<40
	Total HSDA:	998	918	<5	689	640	881	<40
Total HA:		2336	2152	5	1648	660.5	2038	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	152	141	*	134	665	136	<40
	30 - 49	855	771	*	636	700	736	<40
	50 - 64	911	838	*	600	660	783	<40
	65+	418	402	*	278	590	383	<40
Total HA:		2336	2152	5	1648	660.5	2038	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	1770	1654	5	1201	651	1556	<40
Female	566	498	0	447	700	482	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	2152	53	670	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.5 Distribution of Participants by Program Duration FRASER Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	10 years or more	230	216	*	*	*	*	*
	5 years or more	59	43	*	*	*	*	*
	<5 years	82	78	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	371	337	<5	262	680	304	<40
FRASER NORTH	10 years or more	598	559	*	*	*	*	*
	5 years or more	159	144	*	*	*	*	*
	<5 years	210	194	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	967	897	<5	697	680	853	<40
FRASER SOUTH	10 years or more	571	516	*	*	*	490	<40
	5 years or more	162	145	*	*	*	137	<40
	<5 years	265	257	*	*	*	249	<40
	Never on ART	0	0	*	*	*	5	80
	Total HSDA:	998	918	<5	689	640	881	<40
Total HA:		2336	2152	5	1648	660.5	2038	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	1399	1291	0	926	680	1208	<40
	5 years or more	380	332	0	263	700	308	<40
	<5 years	557	529	5	453	620	513	<40
	Never on ART	0	0	0	6	573	9	<40
Total HA:		2336	2152	5	1648	660.5	2038	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
FRASER EAST	32	73	156	563
FRASER NORTH	30	243	269	1665
FRASER SOUTH	45	587	243	2024
Total:	107	903	668	4252

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
FRASER EAST	212
FRASER NORTH	732
FRASER SOUTH	477
Total:	1421

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	0 - 29	11	10	0	11	820	10	<40
	30 - 49	76	65	0	60	710	62	<40
	50 - 64	131	118	0	82	725	109	<40
	65+	97	95	0	78	650	93	<40
	Total HSDA:	315	288	0	231	700	274	<40
RICHMOND	0 - 29	8	7	*	8	655	7	<40
	30 - 49	66	60	*	58	610	59	<40
	50 - 64	78	70	*	62	675	73	<40
	65+	28	28	*	25	580	26	<40
	Total HSDA:	180	165	<5	153	630	165	<40
VANCOUVER	0 - 29	104	95	*	90	665	93	<40
	30 - 49	1160	1008	*	850	700	992	<40
	50 - 64	1475	1365	*	1030	610	1325	<40
	65+	767	729	*	484	610	710	<40
	Total HSDA:	3506	3197	<5	2454	640	3120	<40
Total HA:		4001	3650	<5	2838	650	3559	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	123	112	*	109	680	110	<40
	30 - 49	1302	1133	*	968	695	1113	<40
	50 - 64	1684	1553	*	1174	620	1507	<40
	65+	892	852	*	587	610	829	<40
Total HA:		4001	3650	<5	2838	650	3559	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	3503	3200	*	2368	650	3137	<40
Female	498	450	*	470	670	422	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	3650	56	650	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4 or pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	10 years or more	228	208	0	*	*	198	<40
	5 years or more	40	39	0	*	*	34	<40
	<5 years	47	41	0	*	*	42	<40
	Never on ART	0	0	0	*	*	0	N/A
	Total HSDA:	315	288	0	231	700	274	<40
RICHMOND	10 years or more	100	91	*	79	640	91	<40
	5 years or more	35	30	*	29	680	30	<40
	<5 years	45	44	*	45	620	44	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	180	165	<5	153	630	165	<40
VANCOUVER	10 years or more	2464	2282	*	*	*	2231	<40
	5 years or more	529	446	*	*	*	429	<40
	<5 years	513	469	*	*	*	455	<40
	Never on ART	0	0	*	*	*	5	<40
	Total HSDA:	3506	3197	<5	2454	640	3120	<40
Total HA:		4001	3650	<5	2838	650	3559	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	2792	2581	*	1886	630	2520	<40
	5 years or more	604	515	*	423	740	493	<40
	<5 years	605	554	*	524	640	541	<40
	Never on ART	0	0	*	5	653	5	<40
Total HA:		4001	3650	<5	2838	650	3559	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH SHORE/COAST GARIBALDI	38	61	205	583
RICHMOND	9	113	50	349
VANCOUVER	209	5425	710	12309
Total:	256	5599	965	13241

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	53

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	0 - 29	6	5	0	5	810	*	*
	30 - 49	84	78	0	53	610	*	*
	50 - 64	146	134	0	68	680	*	*
	65+	93	87	0	38	515	*	*
	Total HSDA:	329	304	0	164	600	278	<40
NORTH VANCOUVER ISLAND	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	117	107	0	56	630	92	<40
SOUTH VANCOUVER ISLAND	0 - 29	28	24	*	13	550	25	<40
	30 - 49	205	177	*	72	600	148	<40
	50 - 64	307	289	*	85	640	246	<40
	65+	171	164	*	34	720	157	<40
	Total HSDA:	711	654	<5	204	640	576	<40
Total HA:		1157	1065	<5	424	620	946	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	38	33	*	21	570	32	<40
	30 - 49	317	280	*	141	600	235	<40
	50 - 64	504	470	*	174	645	406	<40
	65+	298	282	*	88	620	273	<40
Total HA:		1157	1065	<5	424	620	946	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	965	887	*	330	600	794	<40
Female	192	178	*	94	675	152	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	1065	58	620	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	10 years or more	229	209	0	104	595	194	<40
	5 years or more	55	54	0	29	750	46	<40
	<5 years	45	41	0	31	540	38	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	329	304	0	164	600	278	<40
NORTH VANCOUVER ISLAND	10 years or more	91	82	0	39	580	71	<40
	5 years or more	10	10	0	5	740	8	<40
	<5 years	16	15	0	12	690	13	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	117	107	0	56	630	92	<40
SOUTH VANCOUVER ISLAND	10 years or more	433	408	*	*	*	*	*
	5 years or more	133	113	*	*	*	*	*
	<5 years	145	133	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	711	654	<5	204	640	576	<40
Total HA:		1157	1065	<5	424	620	946	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	753	699	*	*	*	*	*
	5 years or more	198	177	*	*	*	*	*
	<5 years	206	189	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		1157	1065	<5	424	620	946	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
CENTRAL VANCOUVER ISLAND	68	207	215	985
NORTH VANCOUVER ISLAND	33	63	155	368
SOUTH VANCOUVER ISLAND	48	613	242	2091
Total:	149	883	612	3444

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
CENTRAL VANCOUVER ISLAND	94
NORTH VANCOUVER ISLAND	48
SOUTH VANCOUVER ISLAND	124
Total:	266

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	45	35	0	44	615	31	<40
NORTH WEST	0 - 29	*	*	*	*	*	*	*
	30 - 49	*	*	*	*	*	*	*
	50 - 64	*	*	*	*	*	*	*
	65+	*	*	*	*	*	*	*
	Total HSDA:	72	63	<5	65	610	53	<40
NORTHERN INTERIOR	0 - 29	8	8	*	8	805	8	<40
	30 - 49	66	51	*	59	680	44	<40
	50 - 64	70	65	*	67	490	61	<40
	65+	33	32	*	35	530	28	<40
	Total HSDA:	177	156	<5	169	570	141	<40
Total HA:		294	254	<5	278	590	225	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	14	13	*	14	730	14	<40
	30 - 49	106	81	*	94	640	70	<40
	50 - 64	123	110	*	117	550	98	<40
	65+	51	50	*	53	530	43	<40
Total HA:		294	254	<5	278	590	225	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	194	170	*	185	600	149	<40
Female	100	84	*	93	580	76	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	254	54	600	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.14 Distribution of Participants by Program Duration NORTHERN Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	10 years or more	22	*	0	21	630	*	*
	5 years or more	5	*	0	5	440	*	*
	<5 years	18	*	0	18	635	*	*
	Never on ART	0	*	0	0	N/A	*	*
	Total HSDA:	45	35	0	44	615	31	<40
NORTH WEST	10 years or more	50	42	*	44	615	36	<40
	5 years or more	9	8	*	8	580	6	<40
	<5 years	13	13	*	13	700	11	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	72	63	<5	65	610	53	<40
NORTHERN INTERIOR	10 years or more	118	107	*	115	530	103	<40
	5 years or more	32	25	*	28	585	21	<40
	<5 years	27	24	*	26	680	17	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	177	156	<5	169	570	141	<40
Total HA:		294	254	<5	278	590	225	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	190	165	*	180	575	153	<40
	5 years or more	46	36	*	41	550	31	<40
	<5 years	58	53	*	57	650	41	<40
	Never on ART	0	0	*	0	N/A	0	N/A
Total HA:		294	254	<5	278	590	225	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH EAST	1	*	37	50
NORTH WEST	14	*	94	178
NORTHERN INTERIOR	21	*	129	557
Total:	36	228	260	785

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH EAST	8
NORTH WEST	30
NORTHERN INTERIOR	24
Total:	62

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth

HA	HSDA	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
INTERIOR	EAST KOOTENAY	*	*	*	*	*	*	*
	KOOTENAY BOUNDARY	*	*	*	*	*	*	*
	OKANAGAN	*	*	*	*	*	*	*
	THOMPSON/CARIBOO/SHUSWAP	*	*	*	*	*	*	*
	Total HA:	52	46	<5	44	600	38	<40
FRASER	FRASER EAST	30	25	0	23	640	21	<40
	FRASER NORTH	39	37	0	31	451	33	<40
	FRASER SOUTH	59	53	0	40	564	50	<40
	Total HA:	128	115	0	94	554	104	<40
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	24	0	23	700	23	<40
	RICHMOND	5	5	0	5	460	5	<40
	VANCOUVER	367	340	0	345	490	323	<40
	Total HA:	399	369	0	373	510	351	<40
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	40	0	26	525	39	<40
	NORTH VANCOUVER ISLAND	15	12	0	8	435	8	<40
	SOUTH VANCOUVER ISLAND	44	39	0	15	600	32	<40
	Total HA:	104	91	0	49	550	79	<40
NORTHERN	NORTH EAST	11	8	*	11	500	8	<40
	NORTH WEST	34	28	*	30	540	23	<40
	NORTHERN INTERIOR	64	54	*	63	480	52	<40
	Total HA:	109	90	<5	104	490	83	<40
Total:	792	711	<5	664	530	655	<40	

Sex at Birth	# Enrolled	# on Antiretroviral Treatment	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	495	449	*	406	510	419	<40
Female	297	262	*	258	560	236	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total:	711	55	540	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program

on Antiretroviral Treatment: defined as # of Participants being on antiretroviral treatment in the specified month

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

